The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.
 
John P. Neoptolemos
Research Funding - Nucana (Inst)
 
Daniel H. Palmer
Research Funding - Bristol-Myers Squibb (Inst); Nucana (Inst)
 
Paula Ghaneh
No Relationships to Disclose
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Debiopharm Group; Delcath Systems; Genoscience Pharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Wren Laboratories
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana; Pfizer
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Sanofi (Inst)
 
Jonathan Wadsley
Honoraria - Eisai; Genzyme
Speakers' Bureau - Eisai; Genzyme
Research Funding - AstraZeneca; Genzyme
Travel, Accommodations, Expenses - Celgene; Genzyme; Imaging Equipment Limited; Ipsen
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Alan Anthoney
No Relationships to Disclose
 
Bengt Glimelius
Consulting or Advisory Role - Isofol Medical; PledPharma
 
Stephen Falk
Speakers' Bureau - Merck Serono; Merck Serono; Merck Serono; SERVIER
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Celgene
Other Relationship - SERVIER
 
Ralf Segersvard
No Relationships to Disclose
 
Gary William Middleton
No Relationships to Disclose
 
Paul J. Ross
Honoraria - Eisai; Pierre Fabre; SERVIER; Shire; Sirtex Medical
Consulting or Advisory Role - Eisai; Pierre Fabre; SERVIER; Shire; Sirtex Medical
Speakers' Bureau - Roche; SERVIER; SERVIER; Shire; Shire
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Roche; SERVIER
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Merck KGaA; Roche/Genentech; Servier; Shire; Sirtex Medical
Consulting or Advisory Role - ERYTECH Pharma; Incyte; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical
Speakers' Bureau - Celgene; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
 
Alec McDonald
No Relationships to Disclose
 
Tom David Lewis Crosby
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche
 
Eftychia Eirini Psarelli
No Relationships to Disclose
 
Pascal Hammel
Honoraria - Celgene
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; ERYTECH Pharma (Inst); Halozyme; Mylan; Rafael Pharmaceuticals; VECT-HORUS
Speakers' Bureau - AstraZeneca; Celgene; ERYTECH Pharma; SERVIER; Shire
Research Funding - AstraZeneca (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Halozyme; Ipsen; Pfizer/EMD Serono; Shire; Vect-Horus
 
Thilo Hackert
No Relationships to Disclose
 
Markus W. Buchler
No Relationships to Disclose